Objective: Nitric oxide is a vasodilating and blood pressure lowering substance. To investigate whether calcium antagonists or angiotensin-converting enzyme (ACE) inhibitors increase vascular nitric oxide activity, we assessed systemic and renal vascular sensitivity to nitric oxide synthase inhibition in hypertensives on and off medication. Methods: Ten essential hypertensive patients, aged 22-51 years, were studied 3 times: $4 weeks off medication, after 3 weeks treatment with enalapril 20 mg twice a day and after 3 weeks nifedipine 60 mg / day. Each time, 24-h blood pressure registration was performed, followed by a clearance study to obtain a 3-h dose-response curve for intravenously infused NG-monomethyl-L-arginine (L-NMMA, respectively 0.75, 1.5 and 3.0 mg / kg / h). Results: L-NMMA dose-dependently increased mean arterial pressure with 562 mmHg and systemic vascular resistance with 2465% at maximum dose, whereas cardiac output decreased (all P,0.001). Enalapril and nifedipine treatment decreased blood pressure, while the L-NMMA-induced increase in systemic vascular resistance was potentiated (enalapril: 4567% and nifedipine: 4668%; both P,0.01). L-NMMA also dose-dependently decreased renal blood flow by 5868% at maximum dose (P,0.001), but neither drug potentiated these effects. Conclusion: These results indicate that, in essential hypertensives, antihypertensive therapy with enalapril or nifedipine increases nitric oxide dependency of systemic vascular tone, which may play a role in the blood pressure lowering effect of these drugs. However, this phenomenon cannot be observed in the renal circulation, suggesting a different regulation of endothelium-dependent vasomotion in the hypertensive kidney.
Introduction
controls. Basal systemic NO production may also be reduced in essential hypertensive patients, as assessed by Nitric oxide (NO) has been identified as a vasodilating urinary excretion of the NO metabolite nitrate [5] . substance. It is continuously released from the endoSome forearm studies have claimed amelioration of thelium, keeping the vasculature in a state of basal stimulated and / or basal NO activity in the forearm circularelaxation. It has been suggested that patients with essention after treatment with angiotensin-converting enzyme tial hypertension have an impairment of NO activity.
inhibitors (ACEi) or calcium channel blockers (CCB) in Forearm studies have shown an impaired stimulated NO hypertensive patients [6] [7] [8] , although contrasting findings release, assessed as impaired NO-mediated vasodilation have been reported [9] [10] [11] [12] [13] as well. It is not known whether upon infusion of acetylcholine [1] [2] [3] . Also basal NOthese effects of antihypertensive treatment on local basal activity has been shown to be reduced, as exemplified by a and stimulated NO activity in forearm resistance vessels reduced vasoconstrictor response to the NO synthase can be extrapolated to other vascular beds or total systemic (NOS) inhibitor NG-monomethyl-L-arginine (L-NMMA) vasculature. We have previously shown in healthy vol- [4] in hypertensive patients compared with normotensive unteers that the kidney is more sensitive to intravenous infusion of a NOS inhibitor than total systemic vascular tone, suggesting that basal NO activity is specifically bilaterally for separate blood sampling and infusions. At important in maintaining a low basal renal vascular 09:00 am a priming dose of a solution containing 10% resistance [14] . Therefore, we investigated in patients with inuline, to measure glomerular filtration rate (GFR), and essential hypertension the effect of antihypertensive treat-2.5% para-aminohippuric acid, to measure effective renal ment with either a CCB or an ACEi on basal NO activity plasma flow (ERPF), was given, followed by continuous as assessed by the systemic and renal vasoconstrictor infusion of this solution throughout the remainder of the response to NOS inhibition study. After at least one hour equilibration, three 20-min baseline urine collections were obtained by spontaneous voiding. Blood specimens were drawn at the midpoint of 2. Methods each collection period. Hereafter infusion of L-NMMA wass tarted. L-NMMA (Institut fur Pharmazie, Universitat 2.1. Subjects Leipzig, Germany) was administered intravenously for 3 hours in stepwise increasing doses; steps consisted of a We carried out studies in ten patients (two women and priming dose, followed by continuous infusion, which was eight men, age range, 22 to 51 years) with essential maintained for 1 h. Doses were: I. bolus infusion of 0.75 hypertension. The protocol was approved by the University mg / kg body wt in 3 min, followed by 0.75 mg / kg / hour; Hospital Ethics Committee for Studies in Humans. All II. 0.75 mg / kg in 3 min, followed by 1.5 mg / kg / hour; III. participants gave written informed consent after explana-1.5 mg / kg in 6 min, followed by 3.0 mg / kg / hour. With tion of the protocol. The investigation conforms with the this scheme we aimed to achieve a dose-response curve principles outlined in the Declaration of Helsinki. Patients with brief periods of steady state, appropriate for studying were recruited from the outpatient clinics for hypertension effects in the kidney by means of clearance techniques. and internal medicine of the University Hospital Utrecht.
Recovery was observed for 1 hour after cessation of The diagnosis of essential hypertension was established L-NMMA infusion. before the study by the absence of any clinical evidence of Urine and blood sampling continued at 20-min intervals secondary hypertension and normal serum electrolytes, throughout the study. Blood pressure was recorded at creatinine, urinalysis and renal scintiscan.
5-min intervals using an automated oscillometer device (Omega 1400, Invivo Research Laboratory Inc., Tulsa,
Study design
Oklahoma, USA). Bioimpedance-derived cardiac output (indexed for body surface area, CI) was measured continuEach subject started with a drug-free period of [4] [5] ously (NCCOM3, BoMed Medical Manufacturer Ltd., weeks. At the end of this period, 24-h ambulatory blood Irvine, California, USA) and recorded automatically at pressure (monitor model No. 90207, SpaceLabs Inc., 2-min intervals. In healthy volunteers the assessment of Redmond, Washington, USA) was recorded for documencardiac output with BoMed has been shown to be retation of hypertension. The criteria for acceptance into the producible and particularly accurate for detecting changes study were a mean ambulatory diastolic pressure during [15, 16] . daytime hours (7 AM to 11 PM) greater than 90 mmHg and a mean ambulatory systolic pressure greater than 145 2.3. Biochemical analysis mmHg.
All subjects underwent three clearance studies during Blood and urine samples were analyzed for inuline and which L-NMMA was infused. The first study was after the para-aminohippurate by photometry as described previousperiod off medication. The second and third studies were ly [17, 18] , for osmolality (Advanced Digimatic Osmomeperformed after 3 weeks of treatment with enalapril, 20 mg ter) and for sodium by flame photometry. Cyclic GMP was BID, or nifedipine GITS, 60 mg / day. The two treatment measured in urine samples of the final portion at each periods were separated by a 2-week washout period. The infusion rate. The samples were put directly on ice and order of the treatment periods was randomized. At the end analyzed using a radioimmunoassay kit with tritium-laof each period, 24-h ambulatory blood pressure was belled cyclic GMP (Amersham International plc, Buckinmonitored and 24-hour urine was collected to assess ghamshire, UK). Plasma angiotensin-converting enzyme sodium balance; a clearance study took place on the next activity was measured using a colorimetric method by day. Subjects took their last medication on the morning of hydrolysis of the synthetic substrate L-Hip-His-Leu [19] . the clearance study, at 5 am.
The clearance studies were performed after a light 2.4. Calculations and statistics breakfast at 7 AM, and with subjects in the supine position. After oral water loading sufficient to allow
Mean arterial blood pressure (MAP) was calculated as spontaneous voiding every 20-30 min, adequate diuresis the sum of one-third of the systolic pressure and two-thirds was maintained by drinking amounts of water matching of the diastolic pressure. MAP was divided by CI and RBF, respectively, to estimate systemic vascular resistance index (SVRI) and renal vascular resistance (RVR). Observations of the three 20-min baseline collection periods were averaged to obtain the baseline value on each visit. To make comparisons of the effects of L-NMMA between the different treatment regimens, the values of the last two 20-min collection periods at each infusion rate were averaged and expressed as change from baseline. Effects of treatment on baseline values were explored using a paired t-test. We used one-way ANOVA for repeated measures to assess the effects of L-NMMA, their dose-dependency and the recovery. To assess the effects of treatment on L-NMMA responses, we performed two-way ANOVA for repeated measures, with the L-NMMA infusion dose and the presence of nifedipine or enalapril as independent variables. The interaction variance ratios obtained by this method indicate whether the response to L-NMMA is different between two studies. The L-NMMAinduced percentual increases in vascular resistance in the systemic versus renal circulation were compared using two-way ANOVA for repeated measures, with the L-NMMA infusion dose and the vascular bed as independent variables. If treatment variance ratios reached statistical significance, post-hoc multiple comparisons with the Student-Newman-Keuls test were performed. P,0.05 was considered significant. Results are expressed as mean6standard error.
Results

Effects of L-NMMA during the control study
L-NMMA caused increments in systemic and renal which increased by 562 mmHg at the highest dose (Fig.  1) . CI decreased by 861, 1162 and 1563% (P,0.001), so that calculated SVRI significantly increased by 1162, 1664 and 2465% (P,0.001), for the successive 3 doses (Fig. 2) . Recovery of systemic hemodynamics was creased RVR more than SVRI (P,0.01, two-way achieved within the hour. Renal hemodynamics were also ANOVA), with percentage increase in vascular resistance dose-dependently affected by L-NMMA (Fig. 3) (Fig. 4) . changed. Baseline cGMP excretion was also unchanged compared with off medication. Effective suppression of plasma ACE activity was verified on the day of the clearance study. Enalapril pretreatment significantly potentiated the L-L-NMMA again dose-dependently decreased GFR and NMMA-induced increase in MAP, which increased at the RBF, and profoundly increased RVR (all P,0.001; were similar as during the drug-free period. L-NMMA-4567%, and the apparent difference in basal SVRI beinduced decreases in cGMP excretion during enalapril tween the untreated condition and enalapril treatment was (P,0.001) were also not different compared to off medicaovercome by L-NMMA infusion (Fig. 1) . In the kidney, tion (Fig. 4) . Fig.  1 ). The same was observed for SVRI, which also showed potentiated increments on L-NMMA infusion (P50.01), of 1664, 2866 and 4668% (Fig. 2) . So compared to the untreated state, nifedipine-induced reductions in initial, basal MAP and SVRI were overcome by the maximum Fig. 4 . Baseline urinary cGMP excretion rates (U-cGMP) and L-NMMAinduced changes in essential hypertensive patients off medication (empty dose of L-NMMA (Fig. 1) . Changes in CI were not bars), after 3 weeks enalapril (hatched bars) and after 3 weeks nifedipine significantly different compared to off medication. (Fig. 4) . These effects were not significantly different from the effects of enalapril treatment on systemic hemodynamics. In contrast, nifedipine significantly increased baseline RBF 4. Discussion and GFR (both P,0.05 vs off medication; Fig. 3 ). As with enalapril, basal RVR significantly decreased on nifedipine
The key finding of the present study is that treatment treatment (P,0.01). No change was observed in urine with either nifedipine or enalapril equally decreased basal cGMP excretion.
blood pressure and subsequently increased the L-NMMA When L-NMMA infusion was repeated during nifedipine dose-pressor response in essential hypertensive patients, treatment, again dose-dependent effects on systemic hemoimplicating that, despite different modes of action, both dynamics were observed (all P,0.001). Moreover, reantihypertensive agents increase NO dependency of blood pressure and systemic vascular tone. Measurement of endothelial function in hypertension has yielded conflicting results. Agonist-stimulated NO-activity, Table 1 mostly using acetylcholine and metacholine, demonstrated Baseline values off medication and after 3 weeks enalapril or nifedipine normal [20, 21] medication may have several explanations: First, it could This is the first study in humans demonstrating that L-NMMA dose-dependently decreases renal blood flow. At be a non-specific phenomenon, reflecting a more general every dose, renal vascular resistance increased more than enhancement of constrictor sensitivity secondary to preditotal systemic vascular resistance, suggesting greater NO lation of the vasculature. This seems unlikely, since in dependency of renovascular tone in hypertension. With previous experiments studying a similar patient group and blood flow to the kidneys comprising 20-25% of total using the same methodology, we observed that the recardiac output, the kidneys obviously have a relatively low sponse to another potent vasoconstrictor, i.e. endothelin-1, vascular resistance. To maintain this basal vasodilated was reduced after predilation of the vasculature by enalapstate, regulation of renal NO availability may be speril or nifedipine [25] . The latter observation argues against cifically aimed to counterbalance prevailing local constrica non-specific increase in vascular contractile response to tor activity, rendering basal renal hemodynamics highly vasoconstrictors in general after blood pressure lowering dependent on NO activity. The effects of L-NMMA were treatment with these drugs. Second, the increased vasoconunaffected by either ACEi and calcium channel antagostrictor response to L-NMMA could reflect enhanced nists. Accordingly, L-NMMA-induced renal vasoconstriceffects of alternative vasoconstrictor mechanisms stimution was unaffected by angiotensin-II type I receptor lated by L-NMMA, such as the sympathetic nervous blockers as well as dihydropyridine CCB [41, 42] in system, vasopressin and the renin-angiotensin system. normotensive humans as well as animal models. The However, this explanation is not supported by other potent renal vasoconstrion to NO-inhibition cannot be observations of L-NMMA infusion in humans. Acute Lexplained solely by unopposed action of endogenous NMMA infusion results in decreased, rather than increased angiotensin-II (which would respond to ACEi), nor to sympathetic activity [26] [27] [28] . Also, L-NMMA has been increased endothelin-1 action (which would be attenuated demonstrated not to affect plasma vasopressin [29] . In by CCB [25] ), and hence most likely also reflects withaddition, L-NMMA does not alter renin or aldosterone drawal of nitric oxide in the renal vasculature. levels [29] [30] [31] , whereas the vasoconstrictor response to Strikingly, the unchanged renal vasoconstrictor response L-NMMA in vivo has been shown to be independent of the to L-NMMA during ACEi or CCB is in contrast with the renin-angiotensin system [32] . Therefore, we conclude significantly augmented systemic response to L-NMMA on that the enhanced constrictor response to L-NMMA reflects these therapeutic regimens. One possible explanation is increased basal NO-activity.
that reduction of constrictor tone by ACEi or CCB is The fact that two pharmaceutical compounds with a accompanied by a simultaneous downregulation of NO totally different mode of action are both associated with an activity in the kidney, leading to a similar L-NMMA identical increase in L-NMMA-induced vasoconstriction, response. However, we found that antihypertensive treatsupport the concept that blood pressure lowering per se, ment did not alter basal urinary cyclic GMP excretion, rather than the medication used is the main determinant for which is assumed to be a measure of renal NO activity amelioration of basal NO activity [7, 8] . However, from the [43] . Alternatively, the kidney is characterized by abundant present study we cannot exclude the possibility that mRNA expression and enzymatic activity of other NOmodulation of the L-arginine-NO pathway is a specific synthase isoforms, such as brain-type NO-synthase (NOSeffect of both ACEi and CCB. In this respect, several I) in the macula densa of animal [44, 45] as well as human studies have suggested an improvement of stimulated NO- [44] kidneys, and inducible NO-synthase (NOS-II) in both activity during ACE-inhibition [33] or CCB [34] , which afferent and efferent arterioles of the rat juxta-glomerular occurred independent of the blood pressure lowering effect apparatus [46] . Inhibition of these isoforms may enhance of these drugs. Several mechanisms could contribute to the renal vasoconstrictor response on L-NMMA, thus increased NO bio-availability during ACE-inhibition.
potentially masking any modulation of endothelial NO-ACE-inhibition inhibits the breakdown of bradykinin by activity in the kidney. ACE, which activates the L-arginine-NO pathway in In summary, the infusion of L-NMMA causes dosehuman endothelial cells [35, 36] . In addition, angiotensin II dependent increases in systemic and renal vascular resistactivates endothelial NADH-oxidase, leading to increased ance in patients with essential hypertension. Treatment superoxide production [37] . Superoxide is a major deterwith either enalapril or nifedipine potentiates the systemic minant of NO-availability and thus a reduction in angiotenvasoconstrictor responses, suggesting increased basal NO sin II levels may increase NO availability. Accordingly, tone. However, this phenomenon cannot be observed in the superoxide has recently been shown to be responsible for kidney, suggesting a different regulation of peripheral and part of the hypertensive effect of angiotensin-II in rats renal NO activity in hypertension. [38] . A similar mode of action could also be relevant to the observations with nifedipine. The molecular structure of dihydropyridines possesses several properties which are References characteristic of anti-oxidants [39, 40] . Due to the high partition coefficient resulting in accumulation in lipid 
